These results revealed that the therapeutic action of paeoniflorin in MPGN by ameliorating mesangial cell proliferation and inflammatory response is probably through regulating the PI3K/AKT/GSK-3β pathway. The gene discussed is AKT1; the disease is primary membranoproliferative glomerulonephritis.